SEARCH

SEARCH BY CITATION

References

  • 1
    Schneider HPG. The view of The International Menopause Society on the Women's Health Initiative. Climacteric 2002; 5: 2116.
  • 2
    MacLennan AH, Taylor DH, Wilson DH. Changes in the use of hormone replacement therapy in South Australia. Med J Aust 1995; 162: 42022.
  • 3
    Bachmann GA. A new option for managing urogenital atrophy in postmenopausal women. Cont Obstet Gynecol 1997; 42: 1328.
  • 4
    Cardozo L, Bachmann GA, McClish D, Fonda D, Birgerson L. Meta-analysis of oestrogen therapy in the management of urogenital atrophy in post-menopausal women: second report of the Hormones and Urogenital Therapy Committee. Obstet Gynecol 1998; 92: 7227.
  • 5
    Cummings SR, Black D, Rubin SM. Life time risk of hip, Colles’ or vertebral fracture and coronary heart disease among white postmenopausal women. Arch Intern Med 1989; 149: 24458.
  • 6
    Seeman E. Osteoporosis: trials and tribulations. Am J Med 1997; 103: S7487.
  • 7
    Henry D, Robertson J, O'Connell D, Gillespie W. A systematic review of the skeletal effects of estrogen therapy in postmenopausal women. I. An assessment of the quality of randomized trials published between 1977 and 1995. Climacteric 1998; 1: 92111.
  • 8
    Writing Group for Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002; 288: 32133.
  • 9
    Henry D, Robertson J, O'Connell D, Gillespie W. A systematic review of the skeletal effects of estrogen therapy in postmenopausal women. I. An assessment of the quality of randomized trials published between 1977 and 1995. Climacteric 1998; 1: 92111.
  • 10
    Felson DT, Zhang Y, Hannan MT. The effect of postmenopausal oestrogen therapy on bone density in elderly women. N Engl J Med 1993; 329: 11416.
  • 11
    Ettinger B, Grady D. The waning effect of postmenopausal estrogen therapy on osteoporosis. N Engl J Med 1993; 329: 11923.
  • 12
    Grodstein F, Martinez ME, Platz EA, Giovannucci E, Colditz GA, Kautzy M et al. Postmenopausal hormone use and risk for colorectal cancer and adenoma. Ann Intern Med 1998; 128: 70512.
  • 13
    Calle EE, Miracle-McMahill HL, Thun MJ, Heath CW Jr . Estrogen replacement therapy and risk of fatal colon cancer in a prospective cohort of postmenopausal women. J Natl Cancer Inst 1995; 87: 51723.
  • 14
    Le Blanc ES, Janowsky J, Chan BKS, Nelson HD. Hormone replacement therapy and cognition. JAMA 2001; 285: 148999.
  • 15
    The WHIMS Investigators. The Womens’ Health Initiative Memory Study: a randomized controlled trial. JAMA 2003; 289: 265172.
  • 16
    Zandi PP, Carlson MC, Plassman BL, Welsh-Bohmer KA, Mayer LS, Steffens DC et al. Hormone replacement therapy and incidence of Alzheimer disease in older women. JAMA 2002; 288: 21239.
  • 17
    Wickelgren I. Estrogen stakes claim to cognition. Science 1997; 276: 6758.
  • 18
    Hays J, Ockene JK, Brunner RL, Kotchen JM, Manson JE, Patterson RE et al. Effects of estrogen plus progestin on health-related quality of life. N Engl J Med 2003; 348: 183954.
  • 19
    The Writing Group for the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The PEPI trial. JAMA 1995; 273: 199208.
  • 20
    Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997; 350: 104759.
  • 21
    Colditz GA, Hankinson SE, Hunter DJ, Willett WC, Manson JE, Stampfer MJ et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995; 332: 158993.
  • 22
    Ross RK, Paganni Hill A, Wan PC, Pike AC. Effect of hormone replacement therapy on breast cancer risk, estrogen versus estrogen plus progestin. J Natl Cancer Inst 2000; 92: 32832.
  • 23
    Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton LA, Hoover R. Menopausal estrogen and estrogen−progestin replacement therapy and breast cancer risk. JAMA 2000; 283: 48591.
  • 24
    Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003; 362: 41927.
  • 25
    Willis DB, Calle EE, Miracle-McMahill HL, Heath CW Jr . Estrogen replacement therapy and risk of fatal breast cancer in a prospective cohort of postmenopausal women in the United States. Cancer Causes Control 1996; 7: 44957.
  • 26
    Durna EM, Wren BG, Heller G, Leader LR, Sjoblom P, Eden J. Hormone replacement therapy after a diagnosis of breast cancer: cancer recurrence and mortality. Med J Aust 2002; 177: 34751.
  • 27
    Colditz GA, Willett WC, Stampfer MJ, Rosner B, Speizer FE, Hennekens C. Menopause and the risk of coronary heart disease in women. N Engl J Med 1987; 316: 110510.
  • 28
    Darling GM, Johns JA, McCloud PI, Davis SR. Estrogen and progestin compared with simvastatin for hypercholesterolemia in postmenopausal women. N Engl J Med 1997; 337: 595601.
  • 29
    Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med 1999; 340: 180111.
  • 30
    Grodstein F, Stampfer MJ, Manson JE, Colditz GA, Willett WC, Rosner B et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Eng J Med 1996; 335: 45361.
  • 31
    Davis SR, Goldstat R, Newman A, Berry K, Burger HG, Meredith I et al. Differing effects of low dose estrogen and progestin replacement therapy and pravastatin in hypercholesterolemic postmenopausal women. Climacteric 2002; 5: 34160.
  • 32
    Koh KK, Cardillo C, Bui MN, Hathaway RN, Csako G, Waclawiw MA et al. Vascular effects of estrogen and cholesterol-lowering therapies in hypercholesterolemic postmenopausal women. Circulation 1999; 99: 35460.
  • 33
    Hulley SB, Grady D, Bush T, Furberg C, Herrington D, Riggs B et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. JAMA 1998; 280: 60513.
  • 34
    Cherry N, Gilmour K, Hannaford P, Heagerty A, Khan MA, Kitchener H et al. Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomised controlled trial. The Estrogen in the Prevention of Reinfarction Trial (ESPRIT) team. Lancet 2002; 360: 20018.
  • 35
    Clarke SC, Kelleher J, Lloyd-Jones H, Slack M, Schofield PM. A study of hormone replacement therapy in postmenopausal women with ischaemic heart disease: the Papworth HRT atherosclerosis study. Br J Obstet Gynaecol 2002; 109: 105663.
  • 36
    Viscoli CM, Brass LM, Kernan WN, Sarrel P, Suissa S, Horwitz RIA. Clinical trial of oestrogen replacement after ischaemic stroke. N Engl J Med 2001; 345: 12439.
  • 37
    Hulley S, Furberg C, Barrett-Connor E, Cauley J, Grady D, Haskell W et al. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/Progestin Replacement Study follow-up (HERS II). JAMA 2002; 288: 5866.
  • 38
    Rodriguez C, Patel AV, Calle EE, Jacob EJ, Thun MJ. Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women. JAMA 2002; 285: 146065.
  • 39
    Lacey JV, Mink PJ, Lubin JH, Sherman ME, Troisi R, Hartge P et al. Menopausal hormone replacement therapy and risk of ovarian cancer. JAMA 2002; 288: 3347.